Our CEO, Dr. J. Jean Cui, connected with BiotechTV’s Brad Loncar following our completion of a $100 million financing to gain insight into Dr. Cui’s perspective on #precisionmedicines and how we are working to solve unmet medical needs by re-envisioning #cancer drug development.
Watch the full video here: https://bit.ly/3Isffxy
💼 Did you know IBD can significantly impact a person’s ability to work, with nearly 50% of patients reporting a reduced capacity for daily tasks? This highlights the need for treatments that improve both symptoms and quality of life. https://lnkd.in/emmdNdx5
🔬 In this epsiode of BG Growth Series, we feature Abivax, a pioneering biotechnology company transforming the way we approach IBD treatment by harnessing the body’s natural immune-regulatory mechanisms.
🎥 We sat down with Marc de Garidel, CEO of Abivax, and Corinna zur Bonsen, Board Member, to discuss their relentless pursuit of innovation and their vision for the future of medicine.
💊 Abivax’s lead drug candidate, obefazimod, currently in Phase 3 clinical trials for ulcerative colitis, could revolutionise the management of chronic conditions.
Abivax partnered with Bryan, Garnier & Co for a record-breaking USD 236 million Nasdaq IPO, the largest ever by a French biotech.
👉 Watch this BG Growth Series episode to learn more about Abivax’s journey and their mission to transform global healthcare: https://lnkd.in/emmdNdx5Pierre Kiecolt-Wahl, Vincent Meunier, Theodore de Charsonville, Hugo FischerDidier Blondel, Patrick Malloy, Sophie LACOURREGE#IBD#Biotech#Innovation#Healthcare#BGGrowthSeries#GrowthJourney
The drug-in adhesive patch provided a noninvasive method for extended drug delivery, improving patient experience while ensuring accurate and consistent dosing. Since this invention, Kindeva has remained a leader in transdermal delivery. Dive deeper into our capabilities on our website. https://ow.ly/8XBR50SeRz0#patientcentric#transdermal#drugdelivery
Did you know that 59,68% of Genmab A/S (GMAB)'s value is currently being overlooked by the market?
Genmab A/S is trading at DKK 1604,00 on CSE, while our intrinsic value analysis places it at DKK 3978,58.
🌟 Don't miss out on this chance!
Discover why we believe Genmab A/S is undervalued and how this could be a strategic addition to your portfolio.
Read our detailed analysis here: https://lnkd.in/eEcrGxpC#ValueInvesting#StockAnalysis#InvestmentOpportunities#GMAB#Finance
📄 Analyst Report
Petra Capital Pty Ltd has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share.
The report summarises Orthocell’s revenue growth, and the strong outlook for the Company as it expands its global footprint with regulatory applications either planned or in progress for Remplir and Striate+.
The author noted:
“FY24 saw OCC’s Remplir and Striate products continue to gain traction after ~18 months on market. OCC is now focused on expanding the global footprint of both products. It is targeting 7 new markets, while continuing to execute on growing revenues from existing markets and progressing partnering process for Remplir and non-core tendon cell therapy (with the appointment of US advisors). A renewed Board and strong cash position are supporting this effort. We reiterate BUY, with our $1.28/sh TP offering >3x upside.”
Take a look 👉 https://lnkd.in/gw7A9DAe
$OCC #innovation#biotech#pharma#regenerativemedicine#healthcare#growth
